Table 1.
Ref. | Yr | Age (yr)/sex | Administered | Duration of IFN therapy (wk) | Diagnostic method | Treatment | Outcome |
[1] | 1993 | 60/F | IFNα-2b | 8 | C, R, B | D | Resolved |
[2] | 1994 | 58/F | IFN-α | 12 | C, R, B | D | Resolved |
56/M | IFN-α | 6 | C, R, B | D + S | Resolved | ||
72/F | IFN-α | 3 | C, R | D + S | Improvement | ||
[3] | 1994 | 48/F | IFN-α | 9 | C, R, B | D + S | Resolved |
[4] | 1994 | 62/F | IFN-α | 3 | C, R, B | D + S | Resolved |
[5] | 1996 | 49/F | IFNα-2b, Sho-saiko-to | 6 | C, R, B | D + S | Resolved |
59/M | IFNα-2b, Sho-saiko-to | 4 | C, R, B | D + S | Resolved | ||
42/M | IFNα-2b | 16 | C, R, B | D + S | Resolved | ||
[6] | 1996 | 46/M | IFN-α, Sho-saiko-to | 4 | C, R | D | Resolved |
57/M | IFN-α | 5 | C, R | D | Resolved | ||
59/M | IFN-α | 23 | C, R | D | Resolved | ||
[7] | 2001 | 57/M | IFN-α, ribavirin | 12 | C, R, B | D | Resolved |
[8] | 2002 | 48/F | IFNα-2b, ribavirin | 24 | C, R | D | Resolved |
PEGIFNα-2a, ribavirin | 6 | C, R, B | D + S | Improvement | |||
50/M | IFNα-2b, ribavirin | 4 | C, R, B | D + S | Resolved | ||
[9] | 2003 | 49/M | PEGIFNα-2b, ribavirin | 2 | C, R, B | D + S | Death |
[10] | 2004 | 71/F | PEGIFNα-2a, ribavirin | 20 | C, R, B | D | Resolved |
[11] | 2004 | 51/M | PEGIFNα-2b, ribavirin | 5 | C, R, B | D + S | Death |
[12] | 2005 | 58/F | PEGIFNα-2b, ribavirin | 12 | C, R, B | D + S | Resolved |
PEGIFNα-2a, ribavirin | 12 | C, R | D | Resolved | |||
[13] | 2006 | 68/F | IFNα-2b, ribavirin | 14 | C, R, B | D + S | Resolved |
[14] | 2007 | 47/F | PEGIFNα-2b, ribavirin | 10 | C, R, B | D + S | Resolved |
[15] | 2008 | 43/F | PEGIFNα-2b, ribavirin | 48 | C, R | D + S | Death |
[16] | 2009 | 39/F | PEGIFNα-2a, ribavirin | 36 | C, R, B | D + S | Resolved |
[17] | 2010 | 51/M | PEGIFNα-2b, ribavirin | 4 | C, R, B | D + S | Resolved |
B: Biopsy proven diagnosis; C: Clinical diagnosis; R: Radiological diagnosis; PEGIFN-α: Pegylated interferon α; D: Discontinuation IFN-α; S: Corticosteroids therapy.